Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of First-Line Cadonilimab Plus Axitinib in Patients With Advanced Special Pathological Type Renal Cell Carcinoma: A Prospective, Multi-center, Phase Ib/II Trial

NCT05808608 is registered in ClinicalTrials.gov with Hao Zeng as lead sponsor.

NCT NCT05808608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05808608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of First-Line Cadonilimab Plus Axitinib in Patients With Advanced Special Pathological Type Renal Cell Carcinoma: A Prospective, Multi-center, Phase Ib/II Trial
Lead sponsor
Hao Zeng
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 17, 2023
Completion date
June 30, 2026
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

first-line treatment, non clear cell renal cell carcinoma, renal cell carcinoma, sarcomatoid renal cell carcinoma